Sarepta Therapeutics (SRPT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
18 figures withheld by our checks. Each blank figure names its reason.
81.3mn → 100.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
−25.5% YoY in FY25 · 4.6% of revenue.
$27.4M returned vs $−307.5M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
-32¢ of every revenue dollar becomes profit.
Net margin -32.5% is below the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,956,339.0 | 2,198,237.0 | 1,901,979.0 | 1,243,336.0 | 933,013.0 | 701,887.0 | ▲15.6% | +33.0% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | —A | —A | —A | 701,887.0 | — | — |
Research & development | 653,103.0 | 1,522,066.0 | 804,522.0 | 877,387.0 | 877,090.0 | 771,182.0 | ▲89.2% | +18.5% |
Selling, general & admin | 463,460.0 | 491,716.0 | 557,872.0 | 481,871.0 | 451,421.0 | 282,660.0 | ▼11.9% | +14.8% |
Total operating expenses | 2,005,238.0 | 2,898,018.0 | 1,683,898.0 | 1,511,160.0 | 1,469,214.0 | 1,161,597.0 | ▲72.1% | +25.7% |
Operating incomefeeds ROC rank | −48,899.0 | −699,781.0 | 218,081.0 | −267,824.0 | −536,201.0 | −459,710.0 | — | — |
Other income, net | −43,117.0 | −2,444.0 | 42,693.0 | −252,274.0 | −153,762.0 | 40,762.0 | — | — |
Pretax income | −92,016.0 | −702,225.0 | 260,774.0 | −520,098.0 | −689,963.0 | −418,948.0 | — | — |
Income tax | 22,602.0 | 11,185.0 | 25,535.0 | 15,879.0 | 13,525.0 | −168.0 | ▼56.2% | −6.1% (22→25) |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −114,618.0 | −713,410.0 | 235,239.0 | −535,977.0 | −703,488.0 | −418,780.0 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.36 | −7.13 | 2.34 | −5.80 | −8.03 | −5.15 | — | — |
Diluted shares (mn) | 105.93 | 100.12 | 107.88 | 92.40 | 87.56 | 81.26 | ▼7.2% | +5.4% |
| Margins | ||||||||
Gross margin | —A | —A | —A | —A | —A | 100.0% | — | — |
Operating margin | −2.5% | −31.8% | 11.5% | −21.5% | −57.5% | −65.5% | ▼43.3pp | +33.7pp |
Net margin18th pct in Healthcare | −5.9% | −32.5% | 12.4% | −43.1% | −75.4% | −59.7% | ▼44.8pp | +27.2pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Sarepta Therapeutics' revenue last fiscal year?
Sarepta Therapeutics reported revenue of $2,198.2M in fiscal 2025, up 15.6% from fiscal 2024.
What was Sarepta Therapeutics' net income?
Sarepta Therapeutics reported net income of −$713.4M in fiscal 2025, a net margin of −32.5%.

